Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Status:
Terminated
Trial end date:
2020-09-29
Target enrollment:
Participant gender:
Summary
Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced
squamous cell carcinoma of the head and neck ( metastatic SCCHN) and avelumab +
bempegaldesleukin (NKTR-214) + talazoparib or enzalutamide in metastatic castration resistant
prostate cancer (mCRPC).